Raymond James Downgrades Tvardi Therapeutics to Market Perform

Benzinga Newsdesk Oct 14, 2025 1 year ago

NewsDowngradesAnalyst Ratings

Raymond James analyst Ryan Deschner downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Outperform to Market Perform.